- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00701350
Biomarkers of Intra-amniotic Infection in Women With Preterm Premature Ruptured Amniotic Membranes (PPROM)
Identification of Proteomic Markers of Intra-amniotic Infection (IAI) in Patients With Preterm Premature Rupture of Amniotic Membranes (PPROM)
Study Overview
Status
Conditions
Detailed Description
Preterm premature rupture of the membranes (PPROM) prior to 37 weeks of gestation occurs in approximately 3% of all pregnancies and is associated with one-third of all preterm births (Mercer, 2003). While there are multiple possible etiologies of PPROM, intra-amniotic infection has been implicated as a major contributor, especially at early gestational ages where fetal and neonatal adverse sequelae are frequent (Yoon, et al. 2000). Micro-organisms are recovered from the amniotic fluid obtained by trans-abdominal amniocentesis in 25-40% of women at the time of presentation with PPROM (Simhan and Canavan 2005).
Significant risks to the fetus following PPROM include both complications related to prematurity and to infection or inflammation (ACOG Practice Bulletin 2007). Complications related to prematurity include respiratory distress, intraventricular hemorrhage, and necrotizing enterocolitis. IAI, both clinically apparent and occult, is an important and potentially preventable cause of cerebral white matter injury and cerebral palsy. Ideally, an early diagnosis of IAI in the setting of PPROM is important to allow timely treatment and intervention. Amniocentesis is successful from 40 - 72% of the time with PPROM (Garite, 1982, Blackwell and Berry, 1999). Despite the accuracy for determining infection and the feasibility of amniocentesis, the vast majority of clinicians are reluctant and/or unwilling to perform this procedure in this clinical setting (Capeless and Mead, (1987). There is therefore a critical need for a noninvasive test to identify patients with IAI and PPROM. Timely identification of these sub-clinically infected patients is critical in designing rationale and efficacious treatment strategies that may reduce the fetal and neonatal sequelae associated with PPROM.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Banner Good Samaritan Hospital
-
Tucson, Arizona, United States, 85712
- Tucson Medical Center
-
-
California
-
San Jose, California, United States, 95008
- Good Samaritan Hospital
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Presbyterian St. Luke's Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject is 18 years of age or older
- Subject has singleton gestation
- Subject has fetus with getstational age of at least 23 0/7 days and no greater than 33 6/7 days
Subject has diagnosis of preterm premature rupture of amniotic membranes as determined by at least two of the following:
- Postive pooling,
- Presence of ferning from cervical vaginal fluid swab on an air dried slide,
- Postivie nitrizine pH test, or, in lieu of the criteria listed above
- Positive Amnisure test result
- Positive indigo carmine egress vaginally following instillation at amniocentesis
- Subject is enrolled and has an amniocentesis within 24 hours of membrane rupture
Subject is a candidate for expectant management as evidenced by the following:
- Absence of labor (defined by absence of painful uterine contractions)
- No clinical signs of infection (maternal fever of 37.9 C or greater, fetal heart rate greater than 160 bpm, uterine tenderness, purulent aminorrhea)
- presence of non-reassuring heart tracing
Subject is a candidate for amniocentesis as evidenced by the following:
- Ultrasound reveals pocket of fluid likely to result in successful amniocentesis
- Physician believes that the subject shoudl undergo amniocentesis as part of their routine evaluation of their current problem of PPROM to rule out infection and/or to test for lung maturity
Exclusion Criteria:
- Subject has a fetus with major fetal anomaly (life threatening or requires surgical intervention) or chromosomal aneuploidy
- Subject has pre-existing medical indication for preterm delivery (e.g., pre-eclampsia, refractory hypertension, diabetes with significant complications, active lupus)
- Subject is unable to provide informed consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
1
Women presenting with preterm gestation and ruptured membranes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Expression of protein biomarkers in cervial vaginal fluid
Time Frame: 24 hours of amniotic membrane rupture to delivery
|
24 hours of amniotic membrane rupture to delivery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Richard Porecco, MD, Obstetrix Medical Group
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PGX03-OBX0009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.